Stephen A Beers

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 15

Top Topics

Replacement Therapy

Diffuse Large B Cell Lymphoma

Papillary Thyroid

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Communications biology

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Constantinos Savva, Ellen Copson, Peter W M Johnson, Ramsey I Cutress, Stephen A Beers
Obesity Is Associated with Immunometabolic Changes in Adipose Tissue That May Drive Treatment Resistance in Breast Cancer: Immune-Metabolic Reprogramming and Novel Therapeutic Strategies. Cancers 15 (9) (2023)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sean H Lim, Stephen A Beers, Aymen Al-Shamkhani, Mark S Cragg
Agonist antibodies for cancer immunotherapy: History, Hopes and Challenges. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Constantinos Savva, Ellen Copson, Peter W M Johnson, Ramsey I Cutress, Stephen A Beers
Obesity Is Associated with Immunometabolic Changes in Adipose Tissue That May Drive Treatment Resistance in Breast Cancer: Immune-Metabolic Reprogramming and Novel Therapeutic Strategies. Cancers 15 (9) (2023)
Franziska Heckel, Anna H Turaj, Hayden Fisher, H T Claude Chan, Michael J E Marshall, Osman Dadas, Christine A Penfold, Tatyana Inzhelevskaya, C Ian Mockridge, Diego Alvarado, Ivo Tews, Tibor Keler, Stephen A Beers, Mark S Cragg, Sean H Lim
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Communications biology 5 (1) (2022)
Massimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, Lija James, Aleksandra Bzura, Maria A Lopez, Sonya James, Chuan Wang, Matthew J Ellis, Christopher J Hanley, Josephine F Buckingham, Kerry L Cox, Gareth Hughes, Viia Valge-Archer, Emma V King, Stephen A Beers, Vincent Jaquet, George D D Jones, Natalia Savelyeva, A Emre Sayan, Jason L Parsons, Stephen T Durant, Gareth J Thomas
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance. Cancer research (2022)
Khiyam Hussain, Mark S Cragg, Stephen A Beers
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers 13 (19) (2021)
Joshua M Sopp, Shirley J Peters, Tania F Rowley, Robert J Oldham, Sonya James, Ian Mockridge, Ruth R French, Alison Turner, Stephen A Beers, David P Humphreys, Mark S Cragg
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation. Communications biology 4 (1) (2021)
Lekh N Dahal, Chie-Yin Huang, Richard J Stopforth, Abbie Mead, Keith Chan, Juliet X Bowater, Martin C Taylor, Priyanka Narang, H T Claude Chan, Jinny H Kim, Andrew T Vaughan, Francesco Forconi, Stephen A Beers
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. Journal of immunology (Baltimore, Md. : 1950) 201 (4) (2018)
Thomas R W Tipton, C Ian Mockridge, Ruth R French, Alison L Tutt, Mark S Cragg, Stephen A Beers
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo. Blood 126 (24) (2015)